"Oligonucleotides, Antisense" - Books

Result Filters

Results: 1 to 20 of 91 books (605 items)

<< First< Prev

Page of 5

Select item 50034281.

Clinical Review Report: Inotersen (Tegsedi): (Akcea Therapeutics, Inc.): Indication: Stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan.

Top results in this book Table of Contents

Select item 14152802.

Madame Curie Bioscience Database [Internet].

Austin (TX): Landes Bioscience; 2000-2013.

Top results in this book Table of Contents

Select item 53666723.

Antisense RNA Design, Delivery, and Analysis [Internet].

Arechavala-Gomeza V, Garanto A, editors.

New York: Humana; 2022.

Top results in this book Table of Contents

Select item 50017464.

Pharmacoeconomic Review Report: Inotersen (Tegsedi): (Akcea Therapeutics, Inc.): Indication: Stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan.

Top results in this book Table of Contents

Select item 57048765.

Jasper's Basic Mechanisms of the Epilepsies. 5th edition.

Noebels JL, Avoli M, Rogawski MA, et al., editors.

New York: Oxford University Press; 2024.

Top results in this book Table of Contents

Select item 44036686.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2026 Jan-.

Top results in this book Table of Contents

Select item 14589847.

GeneReviews® [Internet].

Adam MP, Bick S, Mirzaa GM, et al., editors.

Seattle (WA): University of Washington, Seattle; 1993-2026.

Top results in this book Table of Contents

Select item 15027928.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet].

Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

Top results in this book Table of Contents

Select item 16686909.

Holland-Frei Cancer Medicine. 6th edition.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.

Hamilton (ON): BC Decker; 2003.

Top results in this book Table of Contents

Select item 340129410.

Endotext [Internet].

Feingold KR, Adler RA, Ahmed SF, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

Select item 536791011.

Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet].

von Eckardstein A, Binder CJ, editors.

Cham (CH): Springer; 2022.

Top results in this book Table of Contents

Select item 513652612.

Nusinersen for Adolescents and Adults with Spinal Muscular Atrophy: A Review of Clinical Effectiveness [Internet].

Janoudi G, McCormack S.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Sep 10.

Top results in this book Table of Contents

Select item 484387613.

Advancing Gene-Targeted Therapies for Central Nervous System Disorders: Proceedings of a Workshop.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders; Stroud C, Bain L, editors.

Washington (DC): National Academies Press (US); 2019 Sep 20.

Top results in this book Table of Contents

Select item 466314214.

Clinical Review Report: Nusinersen (Spinraza): (Biogen Canada Inc.): Indication: Treatment of patients with 5q SMA [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan.

Top results in this book Table of Contents

Select item 168684015.

Retroviruses.

Coffin JM, Hughes SH, Varmus HE, editors.

Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997.

Top results in this book Table of Contents

Select item 485381616.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 572909017.

Exploring and Exploiting Genetic Risk for Psychiatric Disorders [Internet].

Gordon JA, Binder EB, editors.

Cambridge (MA): MIT Press; 2023.

Top results in this book Table of Contents

Select item 500190018.

CADTH Canadian Drug Expert Committee Recommendation: Inotersen (Tegsedi — Akcea Therapeutics, Inc.): Indication: Treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Dec 20.

Top results in this book Table of Contents

Select item 255337219.

Neurobiology of Huntington's Disease: Applications to Drug Discovery.

Lo DC, Hughes RE, editors.

Boca Raton (FL): CRC Press/Taylor & Francis; 2011.

Top results in this book Table of Contents

Select item 550803820.

RNA, the Epicenter of Genetic Information: A new understanding of molecular biology.

Mattick J, Amaral P.

Abingdon (UK): CRC Press; 2022 Sep 20.

Top results in this book Table of Contents

<< First< Prev

Page of 5

Next >Last >>

Supplemental Content

Images search in Bookshelf

Fig. 1

Illustration of the entire QDB process for evaluation of antisense oligonucleotides in DM1 myoblast

Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts.

Arechavala-Gomeza V, Garanto A, editors. Antisense RNA Design, Delivery, and Analysis [Internet]. New York: Humana; 2022.
Fig. 5

Mechanism of action of antisense oligonucleotides. ANGPTL3-Lrx and APOA(a)-Lrx are antisense oligonucleotides containing three GalNac residues which promote the specific recognition by hepatic ASGPR receptors. Once internalized, they inhibit protein synthesis of ANGPTL3 or apo(a), respectively, by binding the corresponding mRNAs and inducing their degradation

LDL-Cholesterol-Lowering Therapy.

von Eckardstein A, Binder CJ, editors. Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022.
Fig. 5

Design of gapmer antisense oligonucleotides. In a gapmer antisense, segments of PS-DNA and modified RNA are appropriately placed to combine desirable characteristics for antisense agent with both of these modifications. PS-DNA segment provides RNase H activation, and modified RNA segments provide increased nucleolytic stability, affinity to target RNA, decreased poly-anionic characteristics and inflammatory responses

Introduction and History of the Chemistry of Nucleic Acids Therapeutics.

Arechavala-Gomeza V, Garanto A, editors. Antisense RNA Design, Delivery, and Analysis [Internet]. New York: Humana; 2022.
FIGURE 2-1Antisense mechanisms. The binding of antisense oligonucleotides to the messenger RNA (mRNA) can result in degradation, decreased translation, or increased translation of the mRNA through different mechanisms

SOURCE: Presented by C. Frank Bennett, April 23, 2019.

Exploring the Current Landscape of Central Nervous System Gene-Targeted Therapies.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders; Stroud C, Bain L, editors. Advancing Gene-Targeted Therapies for Central Nervous System Disorders: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2019 Sep 20.